Serum Amyloid Alpha in Parapneumonic Effusions
2011

Serum Amyloid Alpha in Parapneumonic Effusions

Sample size: 57 publication Evidence: moderate

Author Information

Author(s): Vagelis Boultadakis, Vasilis Skouras, Demosthenes Makris, Aggeliki Damianaki, Dimitrios J. Nikoulis, Theodoros Kiropoulos, Smaragda Oikonomidi, Irene Tsilioni, Konstantinos Gourgoulianis

Primary Institution: University Hospital of Larissa

Hypothesis

To assess serum amyloid alpha (SAA) pleural fluid levels in parapneumonic effusion (PPE) and to investigate SAA diagnostic performance in PPE diagnosis and outcome.

Conclusion

SAA is increased in complicated PPE, and it might be useful as a biomarker for UPE and CPE diagnosis.

Supporting Evidence

  • SAA levels were significantly higher in complicated parapneumonic effusions compared to uncomplicated ones.
  • CRP levels were also higher in complicated cases.
  • No significant association was found between SAA levels and 6-month outcomes.

Takeaway

This study looked at a protein called SAA in patients with lung fluid buildup. It found that higher SAA levels are linked to more complicated cases, but it doesn't help predict who will have problems later.

Methodology

The study prospectively evaluated 57 patients with PPE, measuring SAA and other inflammatory markers in serum and pleural fluid.

Limitations

SAA levels did not show significant diagnostic performance in predicting clinical outcomes after 6 months.

Participant Demographics

The study included 57 patients, 39 men and 18 women, with a median age of 67.5 years.

Statistical Information

P-Value

P < 0.04 for SAA levels between CPE and UPE; P < 0.01 for CRP levels between EMP and UPE.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2011/237638

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication